Caris Life Sciences Reports Robust Q1 2026 Results with 79% Revenue Growth and Significant Profitability Turnaround

summarizeSummary

Caris Life Sciences reported robust Q1 2026 results, with revenue surging 79% year-over-year and a significant shift to positive Adjusted EBITDA and cash flow from operations, while reaffirming full-year guidance.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  Reported total revenue of $216.2 million, a substantial 79% increase over the corresponding prior year period, driven by 85% growth in molecular profiling services revenue.

• Significant Profitability Turnaround

  Achieved a net loss of only $0.5 million, a dramatic improvement from a $102.6 million net loss in Q1 2025. The company also reported positive Adjusted EBITDA of $26.2 million, reversing a negative $36.2 million in the prior year.

• Positive Cash Flow Generation

  Generated positive net cash from operating activities of $32.9 million and positive free cash flow of $22.5 million, a significant reversal from negative cash flows in Q1 2025.

• Reaffirmed Full-Year Guidance

  Reaffirmed full-year 2026 revenue guidance in the range of $1.0 billion to $1.02 billion, representing 23% to 26% growth, and clinical therapy selection volume growth of approximately 20%.

auto_awesomeAnalysis

Caris Life Sciences delivered exceptionally strong first-quarter 2026 financial results, demonstrating a significant operational and financial turnaround. The company achieved 79% year-over-year revenue growth, moving from a substantial net loss and negative cash flow in the prior year to near breakeven net loss, positive Adjusted EBITDA, and positive operating and free cash flow. This performance, coupled with reaffirmed full-year guidance and recent product advancements, provides a strong positive signal, especially as the stock has been trading near its 52-week low. Investors should monitor if this momentum can be sustained and if the market reacts positively to the improved financial health and operational execution.